Latest Distributions News

iCandy Interactive has announced plans for Lemon Sky Studios to pursue a US IPO on the NYSE American, targeting a US$15 million capital raise, while highlighting strategic pivots in AI and blockchain markets.

RLF AgTech has raised $4.5 million through an institutional placement to accelerate its commercial rollout and meet rising demand amid global fertiliser shortages.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

Radiopharm Theranostics has initiated dosing in its Phase 1 clinical trial of RAD 402, a novel radiolabelled antibody targeting KLK3 in advanced prostate cancer. Early data from the trial’s initial dose levels are expected in the second half of 2026.

BlackRock Investment Management (Australia) Limited has announced estimated cash distributions for a suite of Australian domiciled iShares ETFs, outlining key dates and participation details for investors.

Australia and New Zealand Banking Group Limited (ANZ) has announced a quarterly distribution of AUD 1.4438 per security on its capital notes, payable in June 2026, with a 70% franking component and tax considerations for investors.

Westpac Banking Corporation has announced a fully franked distribution of AUD 1.3609 per Westpac Capital Note 7, reflecting a 5.3991% annualised rate for the quarter ending June 22, 2026.

Paterson Resources has reported impressive shallow gold intercepts at its Grace Gold-Copper Project, setting the stage for a significant resource upgrade and the next phase of drilling.

L1 Group has launched the IPO of L1 Gold Fund Limited, targeting a $900 million raise with founder backing and early closure due to strong investor interest. The fund will list on the ASX in April, continuing the strategy of its predecessor wholesale fund.

Ava Risk Group secures key government contracts and expands its technology trials in Australia, the US, and the Middle East during Q3 FY2026, reinforcing its position in critical infrastructure security.

BCAL Diagnostics is expanding access to its Avantect pancreatic and ovarian cancer blood tests across Australia through partnerships with major pathology providers. This move marks a significant step in making early cancer detection more widely available.

OMG Group has reported a robust 53% increase in net sales for the first two months of FY26, driven by strong growth across retail and ecommerce channels. The company plans a strategic refresh of its Blue Dinosaur product range to maintain momentum.